6 Best Peptides for Frontotemporal Dementia

What to Know Before Choosing a Peptide for Frontotemporal Dementia

Frontotemporal dementia is not a single disease. It is a cluster of disorders caused by progressive degeneration of the frontal and temporal lobes, the brain regions governing personality, behavior, language, and executive function. It is the most common dementia in people under 65, it progresses faster than Alzheimer's disease, and as of 2026, there is no FDA-approved disease-modifying treatment of any kind, peptide or otherwise. The most advanced candidates currently in clinical trials are a monoclonal antibody and an oral small molecule, not peptides. Anyone reading this guide deserves to know that upfront.

That context shapes this list but does not empty it. A compound earns a slot here because researchers have explored it in the context of FTD's underlying biology, because practitioners working in adjacent dementia fields have used and discussed it, or because experimental research has specifically targeted the protein pathologies that drive FTD. Approval status and evidence depth are not the filter. What earns inclusion is genuine engagement with the condition's mechanisms, whether that engagement comes from a randomized controlled trial, a preclinical mouse study, or a documented research discussion about biological plausibility. Where the evidence is thin or absent at the human level, that is stated plainly in each entry.

The compounds in this guide are numbered by how prominently they appear in research and documented use relevant to FTD, not ranked as a recommendation of one over another. There is no "best" compound for FTD in any meaningful clinical sense. The numbers give the list a spine, nothing more. The right choice for any individual, if any choice is appropriate at all, depends on that person's specific FTD subtype, their clinical situation, and the judgment of a qualified physician.

1. Cerebrolysin: The Most Clinically Familiar Option in FTD-Adjacent Research

Cerebrolysin is not a single peptide. It is a complex mixture of low-molecular-weight neuropeptides and free amino acids derived by enzymatic hydrolysis of purified pig brain proteins. That composition makes it biologically rich and scientifically distinctive, and it has built one of the broadest clinical records of any compound in the dementia field, even though that record has not yet extended directly to FTD.

Its clinical foundation rests primarily in Alzheimer's disease, vascular dementia, and stroke recovery. Multiple randomized controlled trials, conducted largely in Eastern Europe, Russia, and China over several decades, have evaluated it in those populations. It is approved and used as a standard therapy in several of those markets. In the United States, it is not FDA-approved for any indication and is not available for legal human use outside of a regulated clinical trial.

The reason Cerebrolysin enters FTD discussions at all is its mechanism. It mimics the activity of several endogenous neurotrophic factors, proteins the brain produces naturally to keep neurons healthy and connected, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Think of those factors as maintenance signals the brain sends to keep its wiring intact. Cerebrolysin delivers a pharmacological version of those signals from outside. For a condition like FTD, where neurons in the frontal and temporal lobes are progressively dying, a compound that supports neuron survival has at least a coherent biological case for investigation.

There is more specific relevance too. Some research has examined whether Cerebrolysin influences tau phosphorylation, the process by which abnormal tau protein forms the aggregates that drive the tauopathy subtypes of FTD, roughly half of all cases. That research is not conclusive and has not been tested in FTD patients specifically, but it connects Cerebrolysin to one of FTD's core molecular problems rather than only to general neurodegeneration. A peptide fraction derived from porcine brain also received FDA Orphan Drug Designation for FTD in 2016, a regulatory acknowledgment that the condition is serious and underserved enough to warrant investigation, though that designation was subsequently withdrawn.

To be precise about what the evidence is and is not: no completed clinical trial has evaluated Cerebrolysin specifically in FTD patients. The case connecting it to FTD is biological plausibility built on top of clinical evidence from other dementia conditions. That is worth naming honestly. Cerebrolysin also requires intravenous or intramuscular administration and is not orally bioavailable, so any use outside a clinical trial context in the US falls outside the legal framework for unapproved investigational compounds.

2. Semax: For Neurotrophic Support and Neuroprotection

Semax is a synthetic heptapeptide, a chain of seven amino acids, designed as an analog of a fragment of adrenocorticotropic hormone (ACTH), a signaling hormone produced by the pituitary gland. It was developed in Russia and has been in clinical use there for roughly three decades, approved for stroke recovery, cognitive impairment, and optic nerve disease. Outside Russia, it is not approved anywhere and is classified as a research compound in the United States.

The core reason Semax enters FTD discussions is its consistent ability to increase BDNF levels. BDNF, or brain-derived neurotrophic factor, acts like a growth and maintenance signal for neurons, particularly in the regions responsible for learning, memory, and higher cognitive function. In neurodegenerative conditions including FTD, BDNF expression tends to fall as neurons die, which removes a natural support mechanism the brain would otherwise use to slow further damage. Semax appears to work partly by amplifying BDNF production, giving surviving neurons a stronger signal to stay functional.

Preclinical research has also shown Semax reducing markers of neuroinflammation and oxidative stress, two processes that contribute to neuronal death across all FTD subtypes. Its influence on dopaminergic and serotonergic signaling is a separate line of interest. The behavioral variant of FTD, the most common subtype, is defined by disinhibition, apathy, and personality change, all involving disrupted neurotransmitter systems. Whether Semax's modulation of those systems would meaningfully affect bvFTD symptoms is an open question that has not been tested in a clinical setting.

The evidence picture for Semax in FTD is this: no human clinical trial data has been published for this compound in FTD as of 2026. The biological mechanisms are plausible and have been studied in adjacent contexts, primarily stroke and general cognitive impairment, but the translation to FTD specifically is speculative. What exists in the FTD context is mechanistic rationale, not clinical confirmation. Semax is available in an intranasal form as well as for subcutaneous injection, which makes it more accessible than an IV-only compound, but its status as a research chemical in the US means any use falls outside standard medical practice.

3. Davunetide: The Only Peptide Actually Tested in an FTD-Spectrum Trial

Davunetide, also called the NAP peptide or AL-108, is an eight-amino-acid peptide derived from Activity-Dependent Neuroprotective Protein (ADNP), a factor the brain naturally produces to support neuron health. It was developed as a neuroprotective compound with a specific proposed mechanism: stabilizing microtubules, the structural scaffolding inside neurons that tau protein is supposed to help maintain. In FTD's tauopathy subtypes, tau becomes hyperphosphorylated and detaches from those microtubules, which then destabilize. Davunetide was designed to shore up that scaffolding directly.

What makes Davunetide uniquely relevant here is that it is the only peptide evaluated in a completed clinical trial targeting an FTD-spectrum condition. The trial studied davunetide in patients with Progressive Supranuclear Palsy (PSP), a tauopathy closely related to FTD and commonly grouped within the FTD syndrome family. PSP shares FTD's tau pathology and its pattern of frontal lobe degeneration, making it one of the closest available test cases for a peptide targeting FTD's core molecular problem.

The result was negative. The trial did not show significant improvement in its primary outcomes. Davunetide did not slow PSP progression to a degree that met the trial's endpoints, and development has not advanced beyond that point. Earlier studies evaluating davunetide in mild cognitive impairment found a satisfactory safety and tolerability profile, so the failure was one of efficacy, not safety. A separate agent tested in an FTD trial, abeotaxane, produced worsening outcomes.

Davunetide's inclusion here reflects both the rigorous test it underwent and what that failure means for the field. It is a real clinical data point in a condition that has very few of them, and it belongs in any honest account of where peptide research stands in FTD-spectrum disease.

4. The CDK5-Blocking Peptide: Precision Tau Targeting in the Laboratory

This compound is at the opposite end of the development spectrum from Davunetide. It is a 12-amino-acid experimental peptide developed at MIT's Picower Institute that has never been tested in humans and is not available for any form of human use. It earns a place in this guide because it is the most mechanistically precise peptide candidate the FTD research literature has produced for the condition's core tau pathology.

The mechanism is specific. CDK5 is an enzyme that regulates important functions inside neurons. In healthy neurons, CDK5 binds to a protein called P35, which keeps it working normally. In the brains of people with FTD, Alzheimer's disease, and Parkinson's disease, P35 gets cleaved into a shorter fragment called P25. P25 drives CDK5 into a hyperactive state, and hyperactive CDK5 over-phosphorylates tau, causing tau to detach from microtubules and form the neurofibrillary tangles that are the hallmark of tauopathy. The MIT peptide mimics a region of CDK5 called the T-loop to block P25 from binding, without interfering with the normal CDK5-P35 interaction. It is a selective block on the specific interaction that goes wrong.

In mouse models engineered to express P25, the compound produced dramatic reductions in neurodegeneration and DNA damage. The researchers have described the selectivity as suggesting it may be "relatively free of clinical side effects" compared to broader CDK5 inhibitors, though that assessment is speculative at the preclinical stage. The transition from mouse brain to human brain is never guaranteed, and for FTD specifically, a tau-focused mechanism addresses only the tauopathy subtype, roughly half of all FTD cases. TDP-43 and FUS pathology would be unaffected.

The compound is here because it represents what targeted peptide science for FTD actually looks like in 2026: experimental, mouse-only, and not something anyone is using, but also the most direct mechanistic approach to one of FTD's core protein pathologies that the peptide literature has produced.

5. CTx1000: Targeting the TDP-43 Pathology That Cerebrolysin and Semax Do Not Reach

CTx1000 is a research-stage compound developed at Macquarie University in Australia, designed to address the other dominant protein pathology in FTD: the toxic accumulation of TDP-43. Approximately 45 percent of FTD cases involve TDP-43 pathology, where TDP-43 protein migrates from the cell nucleus, where it belongs, into the cytoplasm, where it forms toxic aggregates. TDP-43 pathology is also central to ALS, and the overlap between FTD and ALS, often called FTD-ALS spectrum, makes TDP-43-targeting compounds relevant to both conditions simultaneously.

CTx1000 works by isolating a short peptide sequence that blocks the interaction between TDP-43 and a protein called 14-3-3. That interaction is what drives TDP-43 out of the nucleus in the first place. By blocking it, the peptide dissolves existing protein build-ups and allows TDP-43 to resume its normal nuclear function. In mouse models of FTD and ALS, CTx1000 halted disease progression, and no adverse effects were observed in those animal studies.

This compound is not available for human use. No human trial has been conducted, and there is no published timeline for one. It belongs in this guide for the same reason as the CDK5-blocking peptide: the FTD peptide landscape is only honest if it includes what is actually being developed for FTD's specific protein pathologies, not only the compounds that arrived from adjacent conditions. CTx1000 represents the one peptide approach in active development that directly targets TDP-43, the protein problem that Cerebrolysin and Semax, with their general neurotrophic mechanisms, do not specifically address.

6. Oxytocin: For Behavioral Symptoms in the bvFTD Subtype

Oxytocin is a nine-amino-acid peptide hormone produced naturally in the hypothalamus. Most people know it from its roles in social bonding, trust, and emotional connection, which is exactly why it attracted research attention in behavioral variant FTD. The behavioral variant is the most common FTD subtype, and its defining features include loss of empathy, apathy, disinhibition, and blunted emotional responsiveness. Oxytocin's known biology suggests it might influence precisely those behaviors, making the hypothesis at least sensible.

A Phase 2 clinical study tested that hypothesis directly. The result was a small benefit, enough to justify having run the trial but not enough to establish oxytocin as a meaningful treatment for bvFTD behavioral symptoms. It is not in widespread clinical use for FTD, it is not approved for this indication anywhere, and the Phase 2 data does not support it as a primary therapeutic option.

Oxytocin belongs in this list because it is the closest thing the FTD field has to a peptide showing any positive human signal at all, however modest. Davunetide was tested and failed to meet its endpoints. Oxytocin was tested and produced a small signal that fell well short of clinical meaningfulness. Both outcomes are part of the honest picture of where peptide trials in FTD-spectrum disease have actually gone. Oxytocin is approved in other clinical contexts and available by prescription for those uses, but for FTD specifically, any use remains off-label and without meaningful clinical support.

How These Peptides Compare

Frequently Asked Questions

Is there any peptide proven to work for frontotemporal dementia?

No peptide has been proven effective for frontotemporal dementia in a completed clinical trial as of 2026. Davunetide, the most directly tested peptide in an FTD-spectrum condition, did not meet its primary endpoints in a Phase 2 study of Progressive Supranuclear Palsy. Oxytocin showed a small signal in a Phase 2 bvFTD study but not enough to support clinical use, and the compounds with the most mechanistically precise rationale for FTD, the CDK5-blocking peptide and CTx1000, exist only in preclinical animal research.

Why are Cerebrolysin and Semax discussed for FTD if they have never been tested in FTD patients?

Both compounds have clinical records in other neurodegenerative conditions, and their mechanisms overlap with FTD's core pathology in ways that make the biological reasoning coherent. Cerebrolysin delivers neurotrophic factor support that is relevant to any condition involving progressive neuron death. Semax amplifies BDNF, a survival signal that falls as neurons die in FTD. Neither compound's evidence from adjacent conditions translates directly to FTD, and no FTD-specific human trials exist for either. They appear in FTD research discussions because the biological rationale holds, not because clinical evidence in FTD patients supports it.

What are the most advanced FTD treatments in clinical development right now?

The most advanced FTD-specific treatments in development as of 2026 are not peptides. Latozinemab, a monoclonal antibody targeting FTD caused by mutations in the GRN gene, holds FDA Breakthrough Therapy Designation and has completed Phase 3 with topline data announced. VES001, an oral small molecule that raises progranulin levels in GRN-mutation carriers, produced early encouraging results in a Phase Ib/IIa study with a larger trial planned. Patients with GRN-mutation FTD can explore eligibility for ongoing trials through the FTD Registry.

Can peptides be prescribed through telemedicine for FTD?

No peptide can be legally prescribed through telemedicine for FTD in the United States. No peptide is FDA-approved for any indication directly connected to FTD. Cerebrolysin and Semax are approved only in other countries for different indications, and oxytocin's approvals cover uses entirely separate from FTD. The only legal pathway to any investigational FTD treatment in the US is through enrollment in an FDA-regulated clinical trial, and a physician specializing in neurodegenerative disease is the appropriate person to discuss any experimental treatment approach.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for frontotemporal dementia in one place.